Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen

Terasaki, 2004, Predicting kidney graft failure by HLA antibodies: a prospective trial, Am J Transplant, 4, 438, 10.1111/j.1600-6143.2004.00360.x Jordan, 2006, Intravenous Gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients, Am J Transplant, 6, 459, 10.1111/j.1600-6143.2005.01214.x Knight, 2004, The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function, Transplantation, 78, 904, 10.1097/01.TP.0000134399.10352.E4 Meier-Kriesche, 2002, Association of antibody induction with short-and long-term cause-specific mortality in renal transplant recipients, J Am Soc Nephrol, 13, 769, 10.1681/ASN.V133769 Kaden, 1998, Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation, Transplant Proc, 30, 4011, 10.1016/S0041-1345(98)01322-0 Abou, 2003, Intraoperative anti-thymocyte globulin-Fresenius (ATG-F) administration as induction immunosuppressive therapy in kidney transplantation, Mol Immunol, 39, 1089, 10.1016/S0161-5890(03)00071-3 Wang, 2007, One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients, Transplant Proc, 39, 69, 10.1016/j.transproceed.2006.10.007 Mourad, 2004, Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids, Transplantation, 78, 584, 10.1097/01.TP.0000129812.68794.CC Opelz, 1992, Collaborative transplant study — 10-year report, Transplant Proc, 24, 2342 Gjertson, 2002, A multi-factor analysis of kidney regraft outcomes, Clin Transpl, 335 Takemoto, 2004, National conference to assess antibody-mediated rejection in solid organ transplantation, Am J Transplant, 4, 1033, 10.1111/j.1600-6143.2004.00500.x Vella, 2001, Why do we need induction therapy?, 187 Castro, 2004, Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies, Transplant Proc, 36, 874, 10.1016/j.transproceed.2004.03.084 Jirasiritham, 2004, The role of anti-IL-2 receptor in high-risk kidney transplant patients, Transplant Proc, 36, 2110, 10.1016/j.transproceed.2004.08.088 Mariat, 2001, A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients, Transplant Proc, 33, 3192, 10.1016/S0041-1345(01)02357-0 Thibaudin, 1998, Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin, Nephrol Dial Transplant, 13, 711, 10.1093/ndt/13.3.711 Lebranchu, 2002, Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy, Am J Transplant, 2, 48, 10.1034/j.1600-6143.2002.020109.x Abou-Jaoude, 2003, Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation, Mol Immunol, 39, 1083, 10.1016/S0161-5890(03)00072-5 Haririan, 2005, Induction therapy with basiliximab versus Thymoglobulin in African–American kidney transplant recipients, Transplantation, 79, 716, 10.1097/01.TP.0000153506.07816.F0 Kahan, 1999, Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody, Transplantation, 67, 276, 10.1097/00007890-199901270-00016 Brennan, 2003, Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective, randomized, multicenter trial, Am J Transplant, 3, 438 Ducloux, 2004, Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study, Transplantation, 77, 1029, 10.1097/01.TP.0000116442.81259.60 Opelz, 2004, Lymphomas after solid organ transplantation: a collaborative transplant study report, Am J Transplant, 4, 222, 10.1046/j.1600-6143.2003.00325.x Kaden, 1997, Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation, Transplant Proc, 29, 344, 10.1016/S0041-1345(96)00301-6 Yussim, 2000, Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation—a prospective, randomized study, Transpl Int, 13, S293, 10.1111/j.1432-2277.2000.tb02041.x Abudher, 1999, Preoperative ATG bolus treatment increase CsA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients, Transplant Proc, 31, 3361, 10.1016/S0041-1345(99)00826-X Nampoory, 2002, Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction, Transplant Proc, 34, 2916, 10.1016/S0041-1345(02)03487-5 Goggins, 2003, A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients, Transplantation, 76, 798, 10.1097/01.TP.0000081042.67285.91